Suppr超能文献

b型流感嗜血杆菌(Hib)疫苗时代儿童b型流感嗜血杆菌(Hib)疾病的发病率下降。

Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era.

作者信息

Adams W G, Deaver K A, Cochi S L, Plikaytis B D, Zell E R, Broome C V, Wenger J D

机构信息

Meningitis and Special Pathogens Branch, National Center for Infectious Diseases, Atlanta, GA 30333.

出版信息

JAMA. 1993 Jan 13;269(2):221-6.

PMID:8417239
Abstract

OBJECTIVE

Effective Haemophilus influenzae type b (Hib) conjugate vaccines were first licensed for use in US children at least 18 months old in December 1987 and for infants at least 2 months old in October 1990. We evaluated trends in Hib disease associated with licensure of Hib conjugate vaccines.

DESIGN

Data from two sources, an intensive laboratory-based active surveillance system and the National Bacterial Meningitis Reporting System (NBMRS), were used separately to evaluate disease incidence. Data from vaccine manufacturers on Hib vaccine doses distributed in the United States were compared with trends in Hib disease incidence.

RESULTS

The age-specific incidence of Hib disease among children less than 5 years old decreased by 71% from 37 per 100,000 persons in 1989 to 11 per 100,000 persons in 1991 (active surveillance data). Haemophilus influenzae meningitis incidence decreased by 82% between 1985 and 1991 (NBMRS data). Increases in doses of Hib vaccine distributed in the United States coincided with steep declines in Hib disease. Both surveillance systems showed decreased rates of Hib disease in infants less than 1 year old before vaccine was licensed for use in this age group. Haemophilus influenzae type b disease incidence in persons at least 12 years old and pneumococcal meningitis incidence in children less than 5 years old did not change substantially during the same period; therefore, decreased Hib disease in children less than 5 years old is not likely to be explained solely by changes in surveillance sensitivity or decreases in bacterial disease due to changes in medical practice.

CONCLUSION

Our data suggest that conjugate vaccines have already had a marked impact on the incidence of Hib disease in the United States, preventing an estimated 10,000 to 16,000 cases of Hib disease in 1991. The decline of disease in infants less than 1 year old before licensure for this age group warrants further investigation.

摘要

目的

1987年12月,b型流感嗜血杆菌(Hib)结合疫苗首次在美国获得许可,用于至少18个月大的儿童;1990年10月,该疫苗被批准用于至少2个月大的婴儿。我们评估了与Hib结合疫苗许可相关的Hib疾病趋势。

设计

来自两个来源的数据,一个基于实验室的强化主动监测系统和国家细菌性脑膜炎报告系统(NBMRS),分别用于评估疾病发病率。将疫苗制造商在美国分发的Hib疫苗剂量数据与Hib疾病发病率趋势进行比较。

结果

1989年每10万人中37例,到1991年每10万人中11例,5岁以下儿童中Hib疾病的年龄特异性发病率下降了71%(主动监测数据)。1985年至1991年期间,流感嗜血杆菌脑膜炎发病率下降了82%(NBMRS数据)。美国分发的Hib疫苗剂量增加与Hib疾病的急剧下降同时出现。两个监测系统均显示,在该年龄组疫苗获得许可使用之前,1岁以下婴儿的Hib疾病发病率下降。12岁及以上人群的b型流感嗜血杆菌疾病发病率和5岁以下儿童的肺炎球菌脑膜炎发病率在同一时期没有实质性变化;因此,5岁以下儿童Hib疾病的减少不太可能仅仅由监测敏感性的变化或医疗实践变化导致的细菌性疾病减少来解释。

结论

我们的数据表明,结合疫苗已经对美国Hib疾病的发病率产生了显著影响,1991年估计预防了10000至16000例Hib疾病。在该年龄组获得许可之前,1岁以下婴儿疾病的下降值得进一步调查。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验